.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
McKesson
Argus Health
Boehringer Ingelheim
Chinese Patent Office
Julphar
Accenture
Fuji
Cerilliant
Daiichi Sankyo

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,899,717

« Back to Dashboard

Which drugs does patent 6,899,717 protect, and when does it expire?


Patent 6,899,717 protects OZURDEX and is included in one NDA.

This patent has thirty-one patent family members in seventeen countries.

Summary for Patent: 6,899,717

Title: Methods and apparatus for delivery of ocular implants
Abstract:An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
Inventor(s): Weber; David (Danville, CA), Kane; Ingrid (Los Altos, CA), Rehal; Mike (Boulder Creek, CA), Lathrop, III; Robert L. (Santa Clara, CA), Aptekarev; Kenny (Santa Cruz, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:10/246,884
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes6,899,717► Subscribe DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,899,717

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,753,916Methods and apparatus for delivery of ocular implants► Subscribe
7,090,681Methods and apparatus for delivery of ocular implants► Subscribe
7,468,065Apparatus for delivery of ocular implants► Subscribe
7,147,644Apparatus for delivery of ocular implants► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,899,717

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2005108563► Subscribe
Norway20080055► Subscribe
New Zealand538380► Subscribe
New Zealand553891► Subscribe
Poland376478► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Covington
Merck
Medtronic
UBS
Healthtrust
Federal Trade Commission
Harvard Business School
Cerilliant
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot